Biotech | November 20, 2021
Oravax and Genomma JV to commercialise Covid-19 vaccine in Mexico and Latam
Premas Biotech is the developer of the technology for the Covid-19 vaccine and a shareholder in Oravax Medical
Premas Biotech is the developer of the technology for the Covid-19 vaccine and a shareholder in Oravax Medical
It is anticipated to be safe and efficacious by targeting the receptor-binding domain (RBD) of the new coronavirus
The octocopter has successfully delivered 50 vials of Covid-19 vaccines along with syringes in a special container from Chandapura PHC to Haragadde PHC
The submission is based on Phase 2/3 study of mRNA-1273 in children ages 6 to 11
The new facility will provide an important boost to vaccine capacity in Africa
All modules required for regulatory review of Novavax vaccine, including CMC data, are now complete for WHO
The preregistrations are aimed at registering both healthy children and those with comorbidities whereas preference will be given for children with comorbidities
The vaccine can be stored at 2 to 8 degrees celsius and traditional cold chain capabilities will suffice
Following the review of around 20 candidate vaccines by the external advisory group, MVC's vaccine was selected as one of two to be included in the global trial
Filing marks first protein-based vaccine submitted to MHRA for authorization
Subscribe To Our Newsletter & Stay Updated
